Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients (Pts) with Type 2 Diabetes (T2DM) on Basal Insulin Supported Oral Therapy (BOT) (original) (raw)

Diabetes, 2018

Abstract

The prospective observational TOP-2 study investigates the effects of switching pts with T2DM in Germany (n=1,662), Austria and Switzerland, who are uncontrolled (A1c 7.5-10%) on BOT with other basal insulins (BI) to Gla-300 in daily clinical practice. Primary endpoint (EP) is the proportion of pts achieving fasting plasma glucose (FPG) of ≤110 mg/dL after 6 and 12 months, respectively. Secondary EPs include changes in A1c, FPG, body weight (BW) and insulin dose, hypoglycemia incidence and safety. Here we report results of pts recruited at German sites with 12 months results available (n=679). Pts baseline characteristics, efficacy and hypoglycemia EPs are shown in Table 1. Main previous BI was insulin glargine 100 U/mL (Gla-100; 49.2%), most common oral therapy was metformin ± DPP-4 inhibitors (46.4%). At 12 months, proportions of pts at their FPG and A1c targets were 27.0% and 43.2%, respectively. Percentage of pts at FPG and A1c target was max in previous Gla-100 pts (29.3%) and ...

Martin Pfohl hasn't uploaded this paper.

Let Martin know you want this paper to be uploaded.

Ask for this paper to be uploaded.